Skip to main content

Cannabis Canopy Growth pushes into Cannabis beauty and wellness with $73.8-million This Works buy

Part of cannabis and investing

Canopy Growth Corp. said on Wednesday it would buy skincare company This Works for $73.8-million, adding beauty and sleep products to the Canadian weed producer’s portfolio of cannabis oil, hemp and medical capsules.

London-based This Works, set up in 2003 by a former beauty director of Vogue UK and yoga teacher, makes pillow sprays that help users sleep faster, moisturizers to reduce wrinkles, body oils and eye-care products, according to its website.

Canopy Growth said the acquisition fits with its strategy of expanding internationally and would help develop CBD-infused products and brands for the global beauty and wellness space.

Story continues below advertisement

The Canadian company said in February lifestyle expert Martha Stewart would join as an adviser to help develop and launch a line of pot-based products for humans and animals.

Cannabis, primarily CBD – the cannabis derivative reputed to ease anxiety and other ills without marijuana’s high, is being increasingly used in the wellness and beauty business, with companies tapping its properties to offer relief from pain, alongside its anti-inflammatory and anti-acne properties.

LVMH’s Sephora beauty chain has been selling CBD-infused products since 2018, while Ulta Beauty Inc. has Hempz branded product and more recently launched CBD-labelled products.

Some Hollywood celebrities, including Jennifer Aniston, Mandy Moore and Olivia Wilde, have also backed CBD-infused products in media interviews.

Available now: Cannabis Professional, the authoritative news service tailored specifically for professionals in the rapidly evolving cannabis industry. Subscribe now.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter